enGene Holdings Inc reports results for the quarter ended April 30 - Earnings Summary

enGene Therapeutics

12/06/2025 13:33

enGene Holdings Inc ENGN.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended April 30, lower than the same quarter last year, when the company reported EPS of -38 cents.  The mean expectation of ten analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -60 cents to -32 cents per share.

Reported revenue was zero​; analysts expected zero.

enGene Holdings Inc's reported EPS for the quarter was a loss of 51 cents​.

The company reported a quarterly loss of $25.82 million.

enGene Holdings Inc shares had fallen by 28.1% this quarter and lost 51.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for enGene Holdings Inc is $25.00

This summary was machine generated from LSEG data June 12 at 12:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Apr. 30 2025
-0.50
-0.51
Missed
Jan. 31 2025
-0.37
-0.48
Missed
Oct. 31 2024
-0.38
-0.34
Beat
Jul. 31 2024
-0.37
-0.32
Beat